CTLA4 and melanoma: Moreover, different from anti–CTLA-4 trials (1.02; 95% CI, 0.8–1.31; p= 0.942, Supplementary Figure S2E), the pooled HR for anti–PD-1 trials (0.559; 95% CI, 0.358–0.871; p= 0.010, Supplementary Figure S2F) showed significant OS advantage in elderly patients among the melanoma subgroup.